SP Primobol 10 ml is used in the treatment of protein synthesis disorders, cachexia of diverse genesis; trauma, extensive burns after irradiation and infectious diseases; muscular dystrophy, osteoporosis, negative nitrogen balance corticosteroid therapy, hypo and aplastic anemia.
1 vial contains 10 ml solution for injections;
Each ml of Primobol contains 100 mg of Methenolone enanthate.
Route of administration
For intramuscular use only.
Primobol is used in the treatment of protein synthesis disorders, cachexia of diverse genesis; trauma, extensive burns after irradiation and infectious diseases; muscular dystrophy, osteoporosis, negative nitrogen balance corticosteroid therapy, hypo and aplastic anemia.
This medicine is contraindicated in patients that have hypersensitivity to the drug, prostate cancer, breast cancer in men, breast carcinoma in women with hypercalcemia, CPI, severe atherosclerosis, nephrotic syndrome, acute and chronic liver disease, nephritis, pregnancy, lactation.
The drug is administered 1 ml deep intramuscularly every 2 weeks. After the desired result is obtained the administration of 1ml can be done every 3-4 weeks.
Methenolone is an anabolic steroid.When entering the cell nucleus it stimulates the genetic apparatus of the cell, which leads to increased synthesis of DNA, RNA and structural proteins, activates tissue respiration chain enzymes and enhancing tissue respiration, oxidative phosphorylation, ATP synthesis and intracellular macroregion aggregation. It stimulates anabolic processes and inhibits the catabolic one caused by glucocorticoids. Methenolone administration leads to increased muscle mass, reduces fat deposits, improves trophic tissues, promotes calcium deposition in bones, retains sodium and water in the body. The hematopoietic action is determined by the increase of erythropoietin synthesis. Androgenic action may contribute to the development of male secondary sexual characteristics type.
At the first signs of virilization in patients (deepening of the voice, hirsutism, acne, clitoromegaly) administration should be discontinued to avoid irreversible changes. A systematic control of the lipidemia and cholesterol levels should be done.
In women – virilizing symptoms, disorders of the menstrual cycle.
In men: in prepubertal – virilization symptoms, withholding or stopping the growth (calcification of epiphyseal growth zones of tubular bones); during postpubertal – gynecomastia, priapism, inhibition of spermatogenesis.
In men and women – the progression of atherosclerosis, peripheral edema, impaired liver function, changes in blood count, long tubular bones pain.
Overdosage cases have not been reported. DG Winstrol 10